文献速递垂体与肾上腺疾病

经典CYP21A2突变携带者死亡率降低:一项基于全国人群的队列研究

Carriers of a Classic CYP21A2 Mutation Have Reduced Mortality: A Population-Based National Cohort Study.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

研究基于瑞典全国CAH登记库和多代登记库识别1143名CYP21A2突变必然携带者,按性别和年龄匹配一般人群对照,通过死因登记库评估死亡率和死因。携带者总体死亡率显著低于对照(HR 0.79;95%CI 0.678-0.917;P=0.002),感染相关死亡(HR 0.65;95%CI 0.48-0.87;P<0.01)和肺炎死亡(HR 0.22;95%CI 0.06-0.88;P=0.03)显著降低。

要点

  • CYP21A2经典突变携带者总体死亡率低于一般人群对照。
  • 携带者感染相关死亡和肺炎死亡风险显著降低。
  • 更严重突变携带者的死亡率差异更明显。

核心结论

  • 经典CYP21A2突变必然携带者总体死亡率降低,且肺炎死亡风险可能降低。

研究设计与样本

  • 基于瑞典全国CAH登记库和多代登记库识别1143名CYP21A2突变必然携带者(561名男性),通过死因登记库评估死亡率和死因,并与按性别和年龄匹配的一般人群对照比较。

主要发现

  • 携带者总体死亡率低于对照(HR 0.79;95%CI 0.678-0.917;P=0.002)。
  • 更严重突变携带者的死亡率差异更明显。
  • 感染作为死因显著降低(HR 0.65;95%CI 0.48-0.87;P<0.01),肺炎死亡显著降低(HR 0.22;95%CI 0.06-0.88;P=0.03)。
  • 一般人群中女性总体死亡率低于男性,在携带者和对照中均得到确认。

临床怎么用

  • CYP21A2经典突变携带者可能具有生存优势,尤其表现为感染和肺炎死亡风险降低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Congenital adrenal hyperplasia (CAH) is a common monogenic recessive disorder. It has been suggested that CYP21A2 deficiency is common because carriers may have a survival advantage, 1 in 15,000 in most populations. Carriers of CYP21A2 mutations typically do not have clinical symptoms but have a defined phenotype with a more prompt cortisol response to ACTH. OBJECTIVE: We investigated whether the mortality was lower, and determined the cause of death in carriers and population controls. DESIGN: A total of 1143 obligate carriers of a CYP21A2 mutation (561 men) were identified from the Swedish National CAH Registry, encompassing >700 patients and the Multi-Generation Registry to identify their parents. The mortality and cause of death were identified through the Swedish Cause of Death Registry. The hazard ratios (HRs) and 95% CIs were calculated. The results were compared with controls from the general population, matched for sex and age. RESULTS: The overall mortality was lower in carriers of a CYP21A2 mutation compared with the controls (HR 0.79; 95% CI, 0.678 to 0.917; P = 0.002). The difference was more marked among carriers of a more severe mutation. Infection as the cause of death was significantly lower (HR 0.65; 95% CI, 0.48 to 0.87; P < 0.01), particularly for death in pneumonia (HR 0.22; 95% CI, 0.06 to 0.88; P = 0.03). The lower overall mortality among women compared with men in the general population was confirmed among both carriers and controls. CONCLUSION: Obligate CYP21A2 carriers of a classic mutation had a reduced mortality. Specifically, a possible reduced mortality due to pneumonia was seen.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Nordenström A, Svensson J, Lajic S, et al. Carriers of a Classic CYP21A2 Mutation Have Reduced Mortality: A Population-Based National Cohort Study. J Clin Endocrinol Metab. 2019. PMID: 31393570. doi:10.1210/jc.2019-01199

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。